57595-23-0

Basic information

• Product Name: Methyl 4-oxotetrahydrofuran-3-carboxylate
• Synonyms: 3-Furancarboxylic acid, tetrahydro-4-oxo-, methyl ester;Methyl 4-oxotetrahydrofuran-3-carboxylate;Methyl 4-oxotetrahydrofur...;Tetrahydro-4-oxo-3-furoic acid methyl ester;Tetrahydro-4-oxo-3-furancarboxylic Acid Methyl Ester;methyl 4-oxooxolane-3-carboxylate
• CAS NO: 57595-23-0
• Molecular Formula: C₆H₈O₄
• Molecular Weight: 144.12532
• Mol File: 57595-23-0.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 220℃
• Flash Point: 91℃
• Appearance: /
• Density: 1.265
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 10.72±0.20(Predicted)
• CAS DataBase Reference: Methyl 4-oxotetrahydrofuran-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-oxotetrahydrofuran-3-carboxylate(57595-23-0)
• EPA Substance Registry System: Methyl 4-oxotetrahydrofuran-3-carboxylate(57595-23-0)

Safety Data

• RIDADR: UN1993
• Hazardous Substances Data: 57595-23-0(Hazardous Substances Data)

Usage

Description

Methyl 4-oxotetrahydrofuran-3-carboxylate, also known as Tetrahydro-4-oxo-3-furancarboxylic Acid Methyl Ester, is an organic compound with a unique chemical structure. It is characterized by its ester and carboxylate functional groups, which contribute to its reactivity and potential applications in various industries.

Uses

Used in Pharmaceutical Industry:
Methyl 4-oxotetrahydrofuran-3-carboxylate is used as a key intermediate in the synthesis of fused-pyrimidine derivatives. These derivatives have been identified as a series of novel GPR119 agonists, which are potential therapeutic agents for the treatment of type 2 diabetes and obesity. Methyl 4-oxotetrahydrofuran-3-carboxylate plays a crucial role in the development of these new drugs by providing a versatile building block for the construction of the desired molecular structures.

Upstream product

• 292638-85-8 acrylic acid methyl ester 
• 623-50-7 ethyl 2-hydroxyacetate 
• 798541-68-1 methyl acrylate 
• 96-35-5 glycolic acid methyl ester 
• 158001-24-2 (±)-(tetrahydrofuran-3-yl)hydrazine hydrochloride 
• 5417-82-3 (1-ethoxyethylidene)malononitrile 

Downstream Products

• 127956-17-6 methyl 4-(phenylamino)-2,5-dihydrofuran-3-carboxylate 
• 848398-40-3 5,7-dihydrofuro[3,4-d]pyrimidine-2,4(1H,3H)-dione 
• 1186091-02-0 methyl-4-[(4-bromobenzyl)(3-ethoxy-3-oxopropanoyl)amino]-2,5-dihydrofuran-3-carboxylate 
• 1186091-03-1 ethyl 1-(4-bromobenzyl)-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-carboxylate 
• 1186090-70-9 N-({1-[2'-chlorobiphenyl-4-yl-methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycine 
• 1186091-05-3 tert-butyl N-({1-[2'-chlorobiphenyl-4-yl-methyl]-4-hydroxy-2-oxo-1,2,5,7-tetrahydrofuro[3,4-b]pyridin-3-yl}carbonyl)glycinate 

Relevant articles and documents

Synthesis method of tetrahydrofuran-3-ketone

The invention discloses a synthesis method of tetrahydrofuran-3-ketone. The method comprises the following steps of: under an alkaline condition, mixing glycolate (I) and acrylate (II) in a solvent, and carrying out condensation cyclization reaction to obtain 4-formic ester-tetrahydrofuran-3-ketone (III); then, under an acidic condition, performing reflux decarboxylation reaction on the 4-formic ester-tetrahydrofuran-3-ketone (III) so as to obtain thetetrahydrofuran-3-ketone (IV) . According to the synthesis method of the tetrahydrofuran-3-ketone, the yield is greater than 82%; and the method has the advantages of mild and easily-controlled conditions, mild reaction, simple and safe operation and environmental friendliness.

TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS

The present invention provides compounds of Formula (I), or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation

Starting from 1-4 and 7 structural templates, analogues based on bioisosteric replacements (5a-c vs 1, 2 and 6 vs 7) were synthesized for completing the SAR analysis. Interesting binding properties at GluA2, GluK1, and GluK3 receptors were discovered. The requirements for GluK3 interaction were elucidated by determining the X-ray structures of the GluK3-LBD with 2 and 5c and by computational studies. Antinociceptive potential was demonstrated for GluK1 partial agonist 3 and antagonist 7 (2 mg/kg ip).